PharmiWeb Recruiter Blog

WILMINGTON, N.C. (March 2, 2022) –Thermo Fisher Scientific’s PPD clinical research business has been named a winner in Training magazine’s 2022 Training APEX Awards, recognizing its robust enterprise learning programs designed to grow employees’ skills and drive customers’ success.

- Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
- Novel mechanism will be evaluated for the potential to mitigate synaptic dysfunction associated with cognitive deficits across a range of neuropsychiatric and neurodegenerative disorders

Voluntis Announces Partnership with Tilak Healthcare to Help Patients with Cancer Better Manage Ocular Toxicities

• Haleon will be a new world-leader in consumer health with an exceptional portfolio of category-leading brands, including Sensodyne, Voltaren, Panadol and Centrum
• Business is on track to demerge and list as a new company in mid-2022

GlaxoSmithKline plc (GSK) today announced that the new company, to result from the proposed demerger of Consumer Healthcare from GSK in mid-2022, will be called Haleon.

• Collaboration leverages BioNTech’s multi-platform immunotherapy capabilities and Medigene’s T cell receptor (TCR) discovery platform to discover and develop innovative TCR immunotherapies against targets selected by BioNTech
• BioNTech to acquire preclinical PRAME TCR and receive licenses to Medigene’s PD1-41BB switch receptor and precision pairing technologies
• BioNTech will hold exclusive worldwide development and commercialization rights to all TCR therapies arising from the collaboration
• Medigene will receive EUR 26 million upfront from BioNTech, as well as research funding, and will be eligible to receive development, regulatory and commercial milestone payments in addition to royalties and tiered deferred option payments on global net sales

Mainz/Martinsried/Munich, Germany, February 21, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Medigene AG (FSE: MDG1, Prime Standard, “Medigene”), a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies, today announced that they have entered a multi-target research collaboration to develop T cell receptor (TCR) based immunotherapies against cancer. The initial term of the collaboration is three years.

Lilly, Breastcancer.org, For the Breast of Us, Living Beyond Breast Cancer, and Susan G. Komen join together for new education initiative to support people with early breast cancer at high risk for recurrence

PARIS--(BUSINESS WIRE)--On the occasion of World Epilepsy Day (14^th of February 2022), Angelini Pharma, international Italian pharmaceutical company, is committed to provide patients and healthcare professionals with innovative solutions improving the care of patients with epilepsy.

The Cell and Gene Therapy Catapult has partnered with MICA Biosystems to begin the journey of bringing their revolutionary regenerative medicine technology to the MHRA.